JPMorgan raised the firm’s price target on Wave Life Sciences to $17 from $13 and keeps an Overweight rating on the shares. The firm updated it model on the heels of the recent RestorAATion-2 AATD data and Takeda’s opt-out. Key changes include raised probability of success assumptions in alpha-1 antitrypsin deficiency and reclassification of the Huntington’s disease program from a 50/50 split into a wholly owned asset, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences price target raised to $20 from $16 at JonesResearch
- Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302
- Raymond James upgrades Wave Life to Strong Buy on ‘historic’ milestone
- Wave Life Sciences upgraded to Strong Buy from Outperform at Raymond James
- United Air reports Q3 beat, Amazon unveils nuclear energy pacts: Morning Buzz
Questions or Comments about the article? Write to editor@tipranks.com